Rapid Assessment of Nanoparticle Extravasation in a Microfluidic Tumor Model
Open accessThe DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index; 18 of the 37 sources its claims cite were checked for support.
Abstract
High Resolution Image Download MS PowerPoint Slide The development of nanoparticle-based targeted therapeutics for the treatment of cancer requires a well-defined understanding of the tumor microenvironment, which is challenging due to tumor complexity and heterogeneity. Recent advancements in three-dimensional (3D) cell models such as tumor-on-a-chip devices can overcome some of these challenges by providing coculture in vitro systems (tumor surrounded by tubular endothelial cells) that mimic native cellular environments to accurately study the enhanced permeability and retention (EPR) potential of drug delivery systems under flow conditions. However, inducing “leaky” vasculature in endothelial cells surrounding solid tumors in microfluidic devices is not readily controllable and highly dependent on tumor cell identity. Utilizing a microfluidic tumor model (MTM) consisting of a tumor region surrounded by a 3D microvascular network, we have simulated the EPR effect by activating a known regulator of endothelial junction formation and edema: the transient receptor potential vanilloid 4 (TRPV4) ion channel, to rapidly assess extravasation and tumor accumulation of nanoparticles of different sizes and surface chemistries. Treatment with a selective TRPV4 agonist stimulated reorganization of the actin cytoskeleton and disruption of adherens junctions to provide a concentration-dependent or “tunable” leakiness, confirmed by increased tumor uptake of fluorescent dextran macromolecular tracers from the vascular channels. Although this controlled 3D in vitro vascular-edema system may not exemplify all of the complexities of edema mechanisms in vivo, it provides a rapid, materials-focused screening method to assess the extravasation and tumor uptake potential of nanoparticles with distinct properties. We show that the passage of nanoparticles through leaky vasculature is not solely governed by particle size but also by surface chemistry, where surface tertiary amines limit tumor cell association due to unwanted endothelial interactions.
Overview
CoChat Summary
## TL;DR
This paper presents a microfluidic tumor-on-a-chip model in which TRPV4 activation was used to tune endothelial leakiness and rapidly screen nanoparticle extravasation into tumors. In this system, 40 nm carboxylated nanoparticles showed the greatest tumor penetration, and surface chemistry also affected endothelial association, with tertiary amines increasing endothelial interactions.
## Key findings
- The vascularized microfluidic tumor model had a tumor compartment separated from a branched endothelial network by a 2 μm porous interface.
- TRPV4 agonist GSK101 increased endothelial leakiness in a concentration-dependent way: 1, 3, and 10 nM reduced VE-cadherin detection, increased endothelial gaps, and altered F-actin organization.
- In the dextran assay, nonstimulated conditions gave 22.15% fluorescence distribution for FD4 (4 kDa) and 6.22% for RD70 (70 kDa) in the tumor area; with GSK101, uptake increased, with 3 nM considered permissive for 70 kDa macromolecule passage.
- For nanoparticles, 40 nm carboxylic acid particles had the greatest tumor penetration and endothelial/tumor cell association, and 70 nm tertiary amine particles associated more strongly with HUVECs than 70 nm carboxylic acid particles.
- With 3 nM GSK101, nanoparticle extravasation into the tumor increased for all three sizes tested, with a significant increase in MDA-MB-231 cell association and no effect on HUVEC association; the paper also reports 2-fold higher FD4 and 3-fold higher RD70 extravasation.
## Methods
- The study used a SynVivo microfluidic tumor model with MDA-MB-231 breast cancer cells in the tumor compartment and HUVECs in a surrounding 3D vascular network under continuous flow.
- Endothelial barrier leakiness was induced with the TRPV4 agonist GSK1016790A at 1, 3, or 10 nM, and permeability was assessed using FITC-dextran 4 kDa and rhodamine dextran 70 kDa.
- Nanoparticle screening used Cy5-labeled polymer nanoparticles of approximately 40, 70, and 130 nm, plus 70 nm particles with carboxylic acid or tertiary amine surface groups; analysis combined confocal microscopy and flow cytometry.
## Limitations
- The paper states that the model “could not fully represent the complexity of biological systems”, specifically noting the lack of plasma proteins and circulating blood cells that affect nanoparticle properties and nanobio interactions.
- The authors note that HUVECs may not entirely recapitulate all known roles for TRPV4 in tumor vasculature.
- They also say the use of variable flow rates and comparisons with straight-channel devices remain only a theoretical advantage until more rigorous analyses are done.
- Evident from the text: the work is a proof-of-concept in vitro study, so its findings are not direct in vivo validation.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
9 Valid · 1 Not valid · 4 Not checked · 47 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“most likely through Ca 2+ -dependent processes, 35”
What the sources say
- Disputedcites [35] Fiorio Pla, 2012, TRPV4Mediates Tumor-Derived Endothelial Cell Migration Via Arachidonic Acid-Activated Actin Remodeling, Oncogene sourceExperimental — accuracy not yet measured
The Results section on AA-induced Ca2+ responses places actin remodeling upstream of the TRPV4-mediated Ca2+ response, rather than describing F-actin rearrangement as Ca2+-dependent. The Results section on actin remodeling also reports that activating TRPV4 with 4αPDD does not affect actin. Our copy provides no page numbers for these passages. (LLM, conf=0.78)
Checked by a reasoning model — may be wrong.
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“A vascularized MTM has been developed and characterized, consisting of a tumor compartment and a surrounding network of vessels, separated by a 2 μ m wide porous interface (Figure 1A,B). 17,21,26”
What the sources say
- Supportedcites [17] Prabhakarpandian, 2015, Synthetic TumorNetworks for Screening Drug Delivery Systems, J. Controlled Release source
The Design of Synthetic Tumor Network section describes a tumor-growth region adjacent to a microvascular network, with engineered 2 µm leaky gaps between them. The Fabrication and Testing results describe the vascular channel, barrier, and tumor chamber and report that the 2 µm leaky vasculature was functional. (LLM, conf=0.93)
- Supportedcites [21] Tang, 2017, A Biomimetic Microfluidic Tumor Microenvironment Platform Mimicking the EPR Effect for Rapid Screening of Drug Delivery Systems, Sci. Rep. source
The Results section describes vascular and tumor compartments separated by a porous micro-pillar interface. Materials and Methods (Microfabrication of the bMTM) specifies that the compartments communicate through 2 µm pores; the 2 µm measurement describes the pores, rather than the overall width of the interface. The supplied passages have no page numbers. (LLM, conf=0.89)
- Partly supportedcites [26] Prabhakarpandian, 2008, Synthetic Microvascular Networks for Quantitative Analysis of Particle Adhesion, Biomed. Microdevices sourceExperimental — accuracy not yet measured
The Introduction describes a microfluidic network of vessels developed to study particle adhesion, and Results §3.1 reports its fabrication and perfusion. The cited paper does not describe a tumor compartment or a 2 μm porous interface; Methods §2.2 instead describes a semicircular network sealed to glass. No page numbers are available in our copy. (LLM, conf=0.87)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“HUVECs may not entirely recapitulate all known roles for TRPV4 in tumor vasculature. 24,28,35,51,53,66”
What the sources say
- Not checked — no full text of the sourcecites [24] Willette, 2008, Systemic Activation of the Transient Receptor Potential Vanilloid Subtype 4 Channel Causes Endothelial Failure and Circulatory Collapse: Part 2, J. Pharmacol. Exp. Ther. source
- Not checked — no full text of the sourcecites [28] Thorneloe, 2012, An Orally Active TRPV4 Channel Blocker Prevents and Resolves Pulmonary Edema Induced by Heart Failure, Sci. Transl. Med. source
- Partly supportedcites [35] Fiorio Pla, 2012, TRPV4Mediates Tumor-Derived Endothelial Cell Migration Via Arachidonic Acid-Activated Actin Remodeling, Oncogene sourceExperimental — accuracy not yet measured
The Results section reports higher TRPV4 expression and responses in tumor-derived endothelial cells than in the normal microvascular endothelial cells tested, supporting the caution that a normal-cell model may not capture tumor-vascular TRPV4 biology. The paper does not directly compare HUVECs with tumor-derived endothelial cells, so the HUVEC-specific part remains untested (page not provided in our copy). (LLM, conf=0.82)
- Partly supportedcites [51] Thoppil, 2015, TRPV4 Channel Activation Selectively Inhibits Tumor Endothelial Cell Proliferation, Sci. Rep. sourceExperimental — accuracy not yet measured
The Results (page unavailable) report that tumor endothelial cells proliferated more than normal endothelial cells and that TRPV4 activation did not affect normal endothelial-cell proliferation. This supports the caution that normal endothelial cells may not capture TRPV4's roles in tumor vasculature, but the study did not examine HUVECs specifically or establish the full range of those roles. (LLM, conf=0.83)
- Could not verifycites [53] Huh, 2012, A Human Disease Model of Drug Toxicity–Induced Pulmonary Edema in a Lung-on-a-Chip Microdevice, Sci. Transl. Med. sourceExperimental — accuracy not yet measured
The Results (‘Drug testing on-chip’; page unavailable) discuss TRPV4-mediated vascular leakage in a lung model, and the Methods (‘Microfluidic cell culture’; page unavailable) identify the cells as human pulmonary microvascular endothelial cells. Searches for HUVECs and tumor vasculature found no passage addressing whether HUVECs recapitulate TRPV4’s roles in tumor vessels. (LLM, conf=0.76)
- Partly supportedcites [66] Adapala, 2016, Activation of Mechanosensitive Ion Channel TRPV4 Normalizes Tumor Vasculature and Improves Cancer Therapy, Oncogene sourceExperimental — accuracy not yet measured
The Results section on tumor endothelial cells reports lower TRPV4 expression in tumor-derived cells than in normal endothelial cells, and the mouse tumor results link TRPV4 loss to abnormal tumor vessels (page unavailable in our copy). These findings support the concern that normal endothelial cells may not capture every tumor-vascular role of TRPV4, but the paper does not study HUVECs or assess their suitability as a model. (LLM, conf=0.78)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Evidence suggests TRPV4 expression levels are higher in tumor-associated ECs (TECs) relative to normal ECs 35”
What the sources say
- Supportedcites [35] Fiorio Pla, 2012, TRPV4Mediates Tumor-Derived Endothelial Cell Migration Via Arachidonic Acid-Activated Actin Remodeling, Oncogene source
The Results section, under “Tumor-derived endothelial cells display high expression and function of TRPV4” (passage 1; page not provided), reports markedly higher TRPV4 expression in breast tumor-derived ECs than in normal microvascular ECs, and higher expression in renal tumor-derived ECs than in normal glomerular ECs. It concludes that endogenous TRPV4 expression is significantly increased in TECs compared with normal ECs. (LLM, conf=0.94)
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“30 min pretreatment with GSK101 signi fi cantly increased dye uptake into the tumor area over the subsequent 90 min period, in a GSK101 concentration-dependent manner, providing the fi rst indication of the relationship between TRPV4 activity and the extravasation potential of di ff erently sized macromolecules (Figure 3A,B).”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
24 more claims
Create a free account to see all 61 claims and to verify the 6 references still open.
- Probably not a substantial claim. 9
- It may state two separate claims as one. 26
- The quote only partly states this claim. 1
Citations
Cites
Fiji: an open-source platform for biological-image analysis
Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T., Preibisch, S., Rueden, C., Saalfeld, S., Schmid, B., et al. (2012) · Nature Methods · doi:10.1038/nmeth.2019 · Cited by 66,890
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565
Analysis of nanoparticle delivery to tumours
Wilhelm, S., Tavares, A. J., Dai, Q., Ohta, S., Audet, J., Dvorak, H. F., & Chan, W. C. W. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.14 · Cited by 5,218
Nanoparticle therapeutics: an emerging treatment modality for cancer
Davis, M. E., Chen, Z., & Shin, D. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2614 · Cited by 4,233
Tumor Cells Secrete a Vascular Permeability Factor That Promotes Accumulation of Ascites Fluid
Senger, D. R., Galli, S. J., Dvorak, A. M., Perruzzi, C. A., Harvey, V. S., & Dvorak, H. F. (1983) · Science · doi:10.1126/science.6823562 · Cited by 3,972
Dvorak, H. F., Brown, L. F., Detmar, M. J., & Dvořàk, A. M. (1995) · Europe PMC (PubMed Central) · Cited by 3,115
The present and future role of microfluidics in biomedical research
Sackmann, E. K., Fulton, A. L., & Beebe, D. J. (2014) · Nature · doi:10.1038/nature13118 · Cited by 2,995
He, C., Hu, Y., Yin, L., Tang, C., & Yin, C. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.01.065 · Cited by 2,607
Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment
Hobbs, S. K., Monsky, W. L., Yuan, F., Roberts, W. G., Griffith, L., Torchilin, V. P., & Jain, R. K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.8.4607 · Cited by 2,438
Cited by
Xu, M., Qi, Y., Liu, G., Song, Y., Jiang, X., & Du, B. (2023) · ACS Nano · doi:10.1021/acsnano.3c05853 · Cited by 632
Microfluidic Devices: A Tool for Nanoparticle Synthesis and Performance Evaluation
Gimondi, S., Ferreira, H., Reis, R. L., & Neves, N. M. (2023) · ACS Nano · doi:10.1021/acsnano.3c01117 · Cited by 376
Mechanical Stimulation: A Crucial Element of Organ-on-Chip Models
Thompson, C. L., Fu, S., Heywood, H. K., Knight, M. M., & Thorpe, S. D. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.602646 · Cited by 178
Organ-on-a-chip platforms for accelerating the evaluation of nanomedicine
Chen, X., Zhang, Y. S., Zhang, X., & Liu, C. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2020.09.022 · Cited by 107
“interaction between nanomedicine and tumor cells [46,100,105].”
BackgroundHow Advancing are Mesoporous Silica Nanoparticles? A Comprehensive Review of the Literature
Porrang, S., Davaran, S., Rahemi, N., Allahyari, S., & Mostafavi, E. (2022) · International Journal of Nanomedicine · doi:10.2147/ijn.s353349 · Cited by 114
“Some additive features of these nanoparticles include: extravasating across tumor vascular walls, penetration of the tumor interstitium, targetability with the use of surface receptors on cancer cells, and controlling the release of the anticancer drug locally.(93,94) The development of nanocarriers has been influence…”
BackgroundVu, M. N., Kelly, H. G., Wheatley, A. K., Peng, S., Pilkington, E. H., Veldhuis, N. A., Davis, T. P., Kent, S. J., & Truong, N. P. (2020) · Small · doi:10.1002/smll.202002861 · Cited by 90
Self-citationPozzi, S., Scomparin, A., Dangoor, S. I., Ajamil, D. R., Ofek, P., Neufeld, L., Krivitsky, A., Vaskovich‐Koubi, D., Kleiner, R., Dey, P., et al. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.04.001 · Cited by 79
Functionalized Nanoparticles Targeting Tumor-Associated Macrophages as Cancer Therapy
He, Y., Júnior, R. F. D. A., Cruz, L. J., & Eich, C. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13101670 · Cited by 68
Overcoming physiological barriers by nanoparticles for intravenous drug delivery to the lymph nodes
Trac, N. T., & Chung, E. J. (2021) · Experimental Biology and Medicine · doi:10.1177/15353702211010762 · Cited by 63
“used human umbilical vein endothelial cells (HUVECs) as an in vitro model of blood vasculature and reported an over 10-fold increase in the extravasation of 40 nm polystyrene nanoparticles out of the blood endothelium compared to that of 70 nm and 130 nm particles.(81) Kong et al.”
BackgroundLiu, H., Shangguan, W., Zhao, P., Cao, C., Yu, M., Huang, Q., & Cao, L. (2024) · ACS Nano · doi:10.1021/acsnano.4c09803 · Cited by 67
3D bioprinted tumor model with extracellular matrix enhanced bioinks for nanoparticle evaluation
Chen, Y., Xu, L., Li, W., Chen, W., He, Q., Zhang, X., Tang, J., Wang, Y., Liu, B., & Liu, J. (2022) · Biofabrication · doi:10.1088/1758-5090/ac48e4 · Cited by 58
“Therefore, the cell uptake efficiency obtained by traditional 2D planar culture will be exaggerated, which is not conducive to guiding animal experiments and clinical trials [65, 69].”
The Role of in silico Research in Developing Nanoparticle-Based Therapeutics
Jayasinghe, M. K., Lee, C. Y., Tran, T., Tan, R., Chew, S. M., Yeo, B. Z. J., Loh, W. X., Pirisinu, M., & Le, M. T. N. (2022) · Frontiers in Digital Health · doi:10.3389/fdgth.2022.838590 · Cited by 57
Micropathological Chip Modeling the Neurovascular Unit Response to Inflammatory Bone Condition
Neto, E., Monteiro, A. C., Pereira, C. L., Simões, M., Conde, J. P., Chu, V., Sarmento, B. F. C. C., & Lamghari, M. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202102305 · Cited by 53
Guo, Q., Li, L., Gao, G., Liu, R., Einaga, Y., & Zhi, J. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c21332 · Cited by 45
Nanomedicine to Overcome Antimicrobial Resistance: Challenges and Prospects
Zou, W., McAdorey, A., Yan, H., & Chen, W. (2023) · Nanomedicine · doi:10.2217/nnm-2023-0022 · Cited by 46
Hypoxia-sensitive drug delivery to tumors
Filipczak, N., Joshi, U., Attia, S. A., Fridman, I. B., Cohen, S., Konry, T., & Torchilin, V. P. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.11.034 · Cited by 37
Ahmed-Cox, A., Pandžić, E., Johnston, S. T., Heu, C., McGhee, J. B., Mansfeld, F. M., Crampin, E. J., Davis, T. P., Whan, R. M., & Kavallaris, M. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.12.014 · Cited by 39
Self-citationAbolhassani, H., Eskandari, A., Poor, A. S., Zarrabi, A., Khodadadi, B., Karimifard, S., Sahrayi, H., Bourbour, M., & Yaraki, M. T. (2024) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2024.215754 · Cited by 36
Tumor‐On‐A‐Chip Models for Predicting In Vivo Nanoparticle Behavior
de Roode, K. E., Hashemi, K., Verdurmen, W. P. R., & Brock, R. E. (2024) · Small · doi:10.1002/smll.202402311 · Cited by 34
Advances in microfluidic 3D cell culture for preclinical drug development
(2022) · Progress in Molecular Biology and Translational Science · doi:10.1016/bs.pmbts.2021.07.022 · Cited by 23
Targeting Magnetic Nanoparticles in Physiologically Mimicking Tissue Microenvironment
Bhattacharya, S., Kiran Raj, M., Priyadarshani, J., et al. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c07246 · Cited by 22
Nanocarrier‐Based Drug Delivery Systems using Microfluidic‐Assisted Techniques
Alam, M. K. (2023) · Advanced NanoBiomed Research · doi:10.1002/anbr.202300041 · Cited by 24
Sood, A., Kumar, A., Gupta, V. K., Kim, C. M., & Han, S. S. (2022) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.2c01080 · Cited by 22
Cooley, M. B., Wulftange, W. J., Wegierak, D., Goreke, U., Abenojar, E., Gurkan, U. A., & Exner, A. A. (2023) · Lab on a Chip · doi:10.1039/d3lc00514c · Cited by 18
Applications and Considerations for Microfluidic Systems To Model the Blood–Brain Barrier
Floryanzia, S., & Nance, E. A. (2023) · ACS Applied Bio Materials · doi:10.1021/acsabm.3c00364 · Cited by 18
On-microparticle construction of endothelialized liver microtissues for drug testing
Wu, Z., Zheng, Y., Lin, J., Li, Y., Li, Y., Wang, X., & Lin, L. (2023) · Chemical Engineering Journal · doi:10.1016/j.cej.2023.148403 · Cited by 18
Recent progress on nanosystems for nucleic acid delivery
Walia, S., & Mehta, M. J. (2024) · RSC Pharmaceutics · doi:10.1039/d4pm00009a · Cited by 24
Capsules Rheology in Carreau–Yasuda Fluids
Coclite, A., Coclite, G. M., & Tommasi, D. D. (2020) · Nanomaterials · doi:10.3390/nano10112190 · Cited by 15
Microfluidic Reconstitution of Tumor Microenvironment for Nanomedical Applications
Oh, H. J., Kim, J., Kim, H., Choi, N., & Chung, S. H. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202002122 · Cited by 13
Bakhtiar, A., Neah, A. S., Ng, K. Y., & Chowdhury, E. H. (2021) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-021-00547-7 · Cited by 11
Design of Turmeric Rhizome Extract Nano-Formula for Delivery to Cancer Cells
Auychaipornlert, S., Lawanprasert, P. P., Piriyaprasarth, S., Sithisarn, P., & Mangmool, S. (2022) · Molecules · doi:10.3390/molecules27030896 · Cited by 9
Biomaterials meet organ-on-chips – a perspective on tumor modeling
Monteiro, C. F., Deus, I. A., Custódio, C. A., & Mano, J. F. (2024) · International Materials Reviews · doi:10.1177/09506608241303436 · Cited by 10
“144,230,349 A functional microvasculature has implications on the progressive behavior of the tumor, being abnormal blood vessels associated with enhanced tumor invasion.”
Guo, Q., Li, L., Gao, G., Zhao, Q. R., Xia, H., Wang, H., Liu, B., & Zhi, J. (2023) · Carbon · doi:10.1016/j.carbon.2023.118671 · Cited by 7
Ahmed-Cox, A., Macmillan, A., Pandžić, E., Whan, R. M., & Kavallaris, M. (2022) · Cells · doi:10.3390/cells11040642 · Cited by 9
Liposomes are Poorly Absorbed via Lung Lymph After Inhaled Administration in Sheep
Ibrahim, J., Haque, S., Bischof, R. J., Whittaker, A. K., Whittaker, M. R., & Kaminskas, L. M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.880448 · Cited by 6
Self-citationGong, X., Wu, J., Wen, J., Ding, X., Xu, N., Sun, M., Yu, G., Liu, S., Zhang, B., & Liu, H. (2022) · ACS Applied Nano Materials · doi:10.1021/acsanm.2c01027 · Cited by 6
Nanoparticles and Microfluidic Devices in Cancer Research
Maia, F. R., Reis, R. L., & Oliveira, J. M. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-36588-2_10 · Cited by 9
Weakly acidic pH-responsive liposomal content release induced by histidine-modified agents
Kashiwada, A., Taoka, N., Chijimi, Y., et al. (2024) · Organic & Biomolecular Chemistry · doi:10.1039/d4ob00216d · Cited by 5
Recapitulating Solid Stress on Tumor on a Chip for Nanomedicine Diffusive Transport Prediction
Martín–Asensio, A., Dávila, S., Cacheux, J., Lindstaedt, A., Dziadosz, A., Witt, D., Calero, M., Balaž, I., & Rodríguez, I. (2023) · Advanced NanoBiomed Research · doi:10.1002/anbr.202200164 · Cited by 6
Vascular journey and adhesion mechanics of micro-sized carriers in narrow capillaries
Coclite, A. (2020) · Microvascular Research · doi:10.1016/j.mvr.2020.104069 · Cited by 5
“[3–5] Indeed, understanding the specific mechanisms for controlling particle margination, adhesion and extravasation represent a major step for the rational design of anti-cancer nanopharmaceuticals.”
BackgroundYang, Y., Liu, S., & Geng, J. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190730100051 · Cited by 5
Investigation of nanoparticle extravasation pathways in tumor vessel-on-a-chip devices
Dávila, S., Martín–Asensio, A., Diego, E. S., Hernández, J. J., & Rodríguez, I. (2025) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2025.102863 · Cited by 4
Alkhadrawi, H., Dese, K., Panchal, D. M., Pueschel, A. R., Freshwater, K. A., Stewart, A. B., Henderson, H., Elkins, M., Dave, R. T., Wilson, H., et al. (2024) · AIChE Journal · doi:10.1002/aic.18638 · Cited by 1
Ahmed-Cox, A., Pandžić, E., Johnston, S. T., Heu, C., McGhee, J. B., Mansfeld, F. M., Crampin, E. J., Davis, T. P., Whan, R. M., & Kavallaris, M. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.10.26.465839
Self-citationRoutes of Administration for Carriers for Lymphatic Delivery
Tagoe, B., Gyamfi, D., Ofori, E. K., Quaye, B., & Amponsah, S. K. (2024) · Springer eBooks · doi:10.1007/978-3-031-64828-1_15
Avatar: The Way of Complex In Vitro Models in Cancer Nanomedicine
Mahadik, K., Dhurde, T., Sivakumar, M. B., & Rao, N. M. (2025) · Advanced Therapeutics · doi:10.1002/adtp.202500368 · Cited by 1
Computational Predictive Models for Nanomedicines
Sharma, A., & Sharma, N. (2026) · Reference series in phytochemistry · doi:10.1007/978-3-031-69044-0_3-1
Advances in Hybrid Nanoparticle Synthesis Through Microfluidics for In-chip Biomedical Studies
Park, J. H., Kong, C., Park, B., Ahn, J., Gupta, V. K., Makvandi, P., Huh, Y. S., & Jang, S. (2026) · BioChip Journal · doi:10.1007/s13206-026-00259-w · Cited by 2
Magne, T. M., Alencar, L. M. R., Motta, L. M., Fechine, P. B. A., Ricci‐Júnior, E., Shah, S. Q., & Santos‐Oliveira, R. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119869
Николаевич, К. А., Krasnoselskaya, E. N., Khanova, A. R., & Николаевич, Ф. С. (2026) · Biomaterials Advances · doi:10.1016/j.bioadv.2026.215141
Ni, J., Luo, Y., & Guo, R. (2026) · Materials Today Bio · doi:10.1016/j.mtbio.2026.103633
“Examples from non-atrial delivery and fibrosis contexts illustrate possible redesign routes but remain extrapolations [140,141,147,148].”
Metadata
- Authors
- Vu, M. N., Rajasekhar, P., Poole, D. P., Khor, S. Y., Truong, N. P., Nowell, C. J., Quinn, J. F., Whittaker, M., Veldhuis, N. A., & Davis, T. P.
- Affiliations
- Hanoi University of Pharmacy (VN)
- Australian Research Council (AU)
- Monash University (AU)
- University of Warwick (GB)
- Corresponding author
- Veldhuis, Nicholas A.
- Davis, Thomas P.
- ORCID
- Venue
- ACS Applied Nano Materials
- Publisher
- American Chemical Society (ACS)
- Published
- 2019-03-29
- Volume
- 2
- Issue
- 4
- Pages
- 1844-1856
- ISSN
- 2574-0970 (ISSN-L)
- OpenAlex
- W2927037977
- Cited by
- 52
- References
- 72
- Citations by year
- 2026: 6 · 2025: 2 · 2024: 8 · 2023: 9 · 2022: 11 · 2021: 9 · 2020: 6 · 2019: 1
- FWCI
- 1.92
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- ACS Applied Nano Materials (publishedVersion, other-oa)
- Monash University Research Portal (Monash University) (submittedVersion, other-oa)
- Warwick Research Archive Portal (University of Warwick) (submittedVersion)
- Funders
- Takeda Pharmaceuticals U.S.A. (NA)
- Australian Research Council (DE180100076, FL140100052)
- Department of Education and Training (NA)
- Centre of Excellence in Convergent Bio-Nano Science and Technology, Australian Research Council (CE140100036)
- Faculty of Pharmacy and Pharmaceutical Sciences, Monash University (NA)
- Government of Vietnam (NA)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
- Keywords
- nanoparticle extravasation, tumor-on-a-chip, microfluidic tumor model, enhanced permeability and retention effect, adherens junctions, actin cytoskeleton, tumor microenvironment, nanoparticle surface chemistry, nanoparticle size, tumor accumulation, edema, targeted cancer drug delivery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.